Pfizer’s Second Market For Targeted Lung Cancer Drug Xalkori Is Korea
This article was originally published in PharmAsia News
Executive Summary
After winning regulatory approval Dec. 29, Pfizer launches Xalkori in Korea, leveraging a clinical program that has included a significant percentage of Korean patients.